Image Credit: Glucotrack
Glucotrack announced that it has started enrolling a feasibility study for its implantable continuous blood glucose monitoring (CBGM) device. The study will include participants with both type 1 and type 2 diabetes, with data from the study expected to be available within 6-8 weeks.
According to the company, “unlike traditional continuous glucose monitors that measure glucose levels in interstitial fluid, Glucotrack’s CBGM measures glucose directly from blood, aiming to provide real-time readings without the lag time typically associated with interstitial glucose measurements. The CBGM is a long-term implantable device with no on-body external component, designed for three years of continuous, accurate blood glucose monitoring, offering a more convenient and less intrusive glucose monitoring solution.”
The company was founded in 2001 as “Integrity Applications, Inc.” in Or Yehuda, Israel. It changed its name to GlucoTrack, Inc. in November 2021.
Image Credit: Glucotrack
